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Abstract In order to assess the changes in serum calcium
and phosphate and the changes in renal tubular phosphate
reabsorption (TmP/GFR) and to evaluate the association
between these indices and the increase in bone mineral
density (BMD) with once-weekly intermittent administra-
tion of teriparatide (TPTD), the results from the teri-
paratide once-weekly efficacy research (TOWER) trial
were re-analyzed. The TOWER trial studied post-
menopausal women and older men with osteoporosis.
Patients were randomly assigned to receive TPTD 56.5 lg
or placebo for 72 weeks. Of these patients, the present
study investigated those whose calcium and phosphate
levels and lumbar BMD (L-BMD) were measured (TPTD
group, n = 153 and Placebo group, n = 137). The TPTD
group had significantly lower serum phosphate, calcium-
phosphate product, and TmP/GFR at weeks 4, 24, 48, and
72 and urinary fractional calcium excretion (FECa) at
weeks 12, 48, and 72 (p\ 0.05). In the TPTD group, the
serum phosphate and TmP/GFR during early treatment (4,
and 12 weeks) showed a significant positive correlation
with the percent change in L-BMD at weeks 48 and 72.
Based on multivariate analysis corrected for age, BMI, and
L-BMD at the start of treatment, serum phosphate and
TmP/GFR at week 4 showed a significant correlation with
the percent change in L-BMD. This study suggests that the
L-BMD response to once-weekly long-term TPTD treat-
ment is associated with circulating phosphate or with the
status of its renal reabsorption. Preventing decrease in
serum phosphate levels may be important in acquiring
greater L-BMD with once-weekly TPTD.
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Introduction
The homeostasis of circulating calcium and phosphate
plays an important role in bone mass regulation. Calcium
homeostasis is primarily regulated by parathyroid hormone
(PTH), which mediates calcium reabsorption at the renal
distal tubule and calcium mobilization from the bone via
bone resorption and also promotes calcium absorption from
the intestinal tract by vitamin D mediated through vitamin
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mobilizes phosphate from the bone through promoting
bone resorption and promotes phosphate absorption from
the intestinal tract via vitamin D activation [2, 3]. On the
other hand, PTH is also known to suppress phosphate
reabsorption at the renal proximal tubule and promote the
secretion of FGF23, a phosphate diuretic hormone [4].
Collectively, PTH is known to suppress phosphate reab-
sorption in the kidneys and decrease the circulating phos-
phate concentration. Since calcium deficiency secondarily
induces PTH oversecretion, PTH in turn promotes bone
resorption and decreases circulating phosphate concentra-
tion, leading to decreased bone mass and bone mineral
density (BMD) [5]. Moreover, phosphate deficiency blocks
the formation of hydroxyapatite, which is a calcium
phosphate crystal found locally in bone, leading to
decreased BMD. On the other hand, although the secretions
of PTH and FGF23 are stimulated in response to phosphate
oversupply [6], excessive phosphate can cause tunica
media thickening or vascular calcification when adequate
compensation cannot be achieved [7] and is consequently
known to be associated with the incidence of cardiovas-
cular events or heart failure [8–10].
Teriparatide (TPTD) is an analog of PTH (1-34) with
pharmacological actions similar to PTH. Its intermittent
daily or once-weekly administration is known to increase
BMD and significantly suppress fractures [11, 12].
When a single dose of TPTD 56.5 lg was administered,
serum calcium increased transiently from 9.11 to 9.58 mg/
dL around 4 to 6 h after the injection and subsequently
returned to its baseline concentration until 24 h after the
injection. At the same time, a decrease in urinary calcium
excretion was observed at 4 h and again the decrease was
transient. After TPTD administration, an increase in uri-
nary phosphate excretion was observed at 2 and 6 h after
the drug injection, but the increase was transient. Serum
phosphate level was decreased transiently as a result, but
subsequently returned to the level that was not statistically
different from that of baseline value [13]. When patients
receive TPTD 56.5 lg once-weekly repeatedly, serum
calcium changes similarly, but without attenuation in its
effects for 24 weeks [14]. On the other hand, the serum
phosphate level just before TPTD administration gradually
decreases compared to the level at the start of treatment.
Whether these changes in calcium and phosphate during
once-weekly intermittent TPTD treatment are associated
with the increase in BMD has not been previously assessed.
Recently, the associations among changes in calcium
and phosphate, changes in BMD, and changes in intima-
media thickness (IMT) with daily TPTD treatment were
investigated. The results showed that the changes in cal-
cium and phosphate were not significantly correlated with
BMD [15].
In the present study, to clarify whether the earlier
changes in calcium and phosphate metabolism can predict
the later change of BMD, the changes in serum calcium
and phosphate, the changes in renal tubule phosphate
reabsorption, and the association between these changes




Data from the TOWER trial, a randomized, controlled trial
conducted in Japan with the objective of determining the
effects of TPTD on suppressing bone fractures in post-
menopausal women and men with osteoporosis, were used
in the present analysis [12]. Patients were randomly
assigned to receive once-weekly subcutaneous injections of
TPTD 56.5 lg or placebo for 72 weeks. All patients
received daily oral supplements of calcium 610 mg, vita-
min D 400 IU, and magnesium 30 mg.
Clinical Laboratory Measurements
Blood and urine samples were collected prior to each
TPTD treatment. Samples were analyzed collectively at a
central laboratory. Adjusted serum calcium, serum phos-
phate, serum creatinine, urinary calcium, urinary phos-
phate, and urinary creatinine concentrations were measured
at weeks 0, 4, 24, 48, and 72. At each time point, adjusted
serum calcium-phosphate product, urinary fractional cal-
cium excretion (FECa), and the phosphate reabsorption
index TmP/GFR were calculated. Equations for FECa and
TmP/GFR are as follows:
FECa (%) = (Urinary calcium 9 Serum creatinine) 9
100/(Urinary creatinine 9 Serum calcium)
TmP/GFR = Serum phosphate 9 (1 - (Urinary phos-
phate 9 Serum creatinine)/(Serum phosphate 9 Urinary
creatinine))
BMD Measurement
Lumbar (L)-BMD was measured at each medical institu-
tion at weeks 0, 24, 48, and 72, and DXA data of the L2-4
area were determined using two types of instruments [QDR
(Hologic, Bedford, MA) and DPX (GE Healthcare, Fair-
field, CT)]. DXA data were re-analyzed collectively at a
central laboratory and measured by a specialist. Percent
changes between late treatment (weeks 48 and 72) and pre-
treatment levels were calculated.
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Statistical Analysis
All continuous variables are expressed as mean ± standard
deviation (SD). Adjusted serum calcium, serum phosphate,
serum calcium-phosphate product, FECa, and TmP/GFR
were compared between groups for each time point (t-test).
The associations between these variables during early
treatment (weeks 4 and 12) and the percent change in
L-BMD during late treatment (weeks 48 and 72) were
evaluated using Pearson’s correlation coefficient. Variables
that showed significant correlations with L-BMD were
subjected to multivariate analysis using age, BMI, and
initial L-BMD as factors for adjustment. Additionally,
significant explanatory variables were split at the median of
the TPTD group into high and low groups, and the dif-
ference in the actual percent changes in L-BMD was
compared with the t-test between the two groups for each
variable. p\ 0.05 was considered significant.
Results
Of the 578 patients who received randomized treatment in
the TOWER trial, those whose clinical laboratory values of
calcium and phosphate, as well as L-BMD, were measured
(TPTD group, n = 153; Placebo group, n = 137) were
investigated. The patient characteristics of each group are
shown in Table 1. Significant differences were not evident
between the groups in any of the parameters.
L-BMD percent changes during late treatment in the
TPTD group and Placebo group were 5.8 ± 4.6 %
(n = 113) and 0.6 ± 3.8 % (n = 138) at 48 weeks and
6.7 ± 5.3 % (n = 107) and 0.3 ± 4.5 % (n = 130) at
72 weeks, respectively, showing significant differences
between the groups at both time points (p\ 0.001).
Adjusted serum calcium, phosphate, calcium-phosphate
product, FECa, and TmP/GFR at each time point are shown
in Fig. 1. Serum calcium was not significantly different
between the groups. Serum phosphate, calcium-phosphate
product, and TmP/GFR were significantly lower in the
TPTD group at weeks 4, 24, 48, and 72 (p\ 0.05). FECa
was significantly lower in the TPTD group at weeks 12, 48,
and 72 (p\ 0.05).
Table 2 shows the correlation between adjusted serum
calcium, phosphate, calcium-phosphate product, FECa, and
TmP/GFR in the TPTD group during early treatment
(weeks 4 and 12) and the percent change of L-BMD during
late treatment (weeks 48 and 72). Serum phosphate and
TmP/GFR at both 4 and 12 weeks showed a significant
positive correlation with the percent change in L-BMD at
both 48 and 72 weeks (p\ 0.05).
Table 3 shows the results of the multivariate analysis
using serum phosphate and TmP/GFR, which are variables
that showed significant differences during early treatment
(week 4). Based on the analysis adjusted for age, BMI, and
initial L-BMD, serum phosphate and TmP/GFR at week 4
showed a significant association with the percent change of
L-BMD (p\ 0.05). Serum phosphate and TmP/GFR at
week 4 were split at the median (3.5 and 3.16 mg/dL,
respectively) into high and low groups, and the percent
changes in L-BMD at 72 weeks were compared between
these groups (Fig. 2). Greater L-BMD was observed in the
serum phosphate C3.5 mg/dL group, though the difference
was not significant, and significantly greater L-BMD was
observed in the TmP/GFRC3.16 mg/dL group (p = 0.032).
Discussion
In the present study, the changes in calcium, phosphate,
calcium excretion, and phosphate reabsorption were
examined in patients who received once-weekly long-term
TPTD treatment. With TPTD, serum phosphate and cal-
cium-phosphate product decreased significantly. Moreover,
the calcium excretion index FECa and the phosphate
reabsorption index TmP/GFR also decreased. The associ-
ations between these decreases and the percent change in
L-BMD were also examined during late TPTD treatment to
Table 1 Baseline
characteristics
Item Placebo (n = 153) TPTD (n = 137) p
Mean SD Mean SD
Age (years) 74.9 5.9 74.2 5.4 0.348
BMI (kg/m2) 23.0 3.2 22.9 3.1 0.823
Adjusted serum calcium (mg/dL) 9.6 0.4 9.5 0.4 0.237
Serum phosphate (mg/dL) 3.6 0.4 3.6 0.5 0.671
Adjusted serum calcium 9 phosphate 34.6 4.9 34.2 4.7 0.459
FECa (%) 1.3 0.8 1.3 0.8 0.520
TmP/GFR (mg/dL) 3.3 0.5 3.2 0.4 0.553
L-BMD (g/cm2) 0.72 0.12 0.71 0.12 0.312
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demonstrate that Tmp/GFR was positively correlated with
the percent increase in L-BMD. These results indicate that
the smaller the decrease in renal tubule phosphate reab-
sorption with once-weekly TPTD treatment, the better it is
for increasing BMD. These were the first observations
indicating the clinical significance of adequate phosphate
response to TPTD administration for more efficient
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(b) (c)
(d) (e)
Fig. 1 Changes of calcium, phosphate, and the reabsorption rate. a adjusted serum calcium, b serum phosphate c serum calcium 9 phosphate,
d urinary fractional calcium excretion (FECa) and e phosphate reabsorption index (TmP/GFR). TPTD teriparatide. * p\0.05, values aremean ± SD
Table 2 Correlations of calcium and phosphate with the change in L-BMD
Parameter Weeks Change in L-BMD at 48 weeks Change in L-BMD at 72 weeks
R p R p
Adjusted serum calcium 4 -0.114 0.230 0.026 0.792
12 -0.134 0.159 -0.059 0.550
Serum phosphate 4 0.215 0.022 0.205 0.034
12 0.233 0.013 0.218 0.024
Adjusted serum calcium 9 phosphate 4 0.163 0.084 0.186 0.055
12 0.162 0.087 0.169 0.082
FECa 4 -0.010 0.920 0.001 0.991
12 -0.015 0.877 -0.037 0.705
TmP/GFR 4 0.231 0.014 0.228 0.019
12 0.288 0.002 0.312 0.001
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In addition, they suggest the clinical importance of moni-
toring serum phosphate levels during TPTD therapy.
When TPTD is given, there is a transient elevation in the
serum calcium concentration and a transient decrease in the
phosphate concentration, both of which return to their
respective baseline levels by the subsequent TPTD treat-
ment [13]. However, the present results suggest that the
decrease in renal phosphate reabsorption initiated by TPTD
administration lasts for a long time in quite a few of sub-
jects. Given that the biological actions of exogenous PTH
after a single TPTD injection do not continue over a day
because circulating levels of TPTD returned to basal value
until 7 h after injection [13, 14], the decrease in serum
phosphate is possibly due to the decrease in Tmp/GFR that
might be caused by some intrinsic mechanisms, such as
endogenous PTH, FGF23, and vitamin D actions that
regulate phosphate metabolism. For example, exogenously
administered TPTD has been shown to increase the circu-
lating level of FGF23 [16], which could inhibit renal
phosphate reabsorption and vitamin D activation. Thus,
once-weekly TPTD administration might decrease serum
phosphate levels via the stimulation of FGF23 when vita-
min D actions are insufficient to prevent its decrease, for
instance, in the presence of vitamin D insufficiency/defi-
ciency. Although mean values of serum endogenous PTH
were suppressed by TPTD administration until 6 days [13],
endogenous PTH levels might also be dependent on vita-
min D sufficiency. Then, another possibility is that rela-
tively lower serum phosphate levels might be observed in
subjects with relatively higher endogenous PTH levels in
the presence of vitamin D insufficiency/deficiency.
With regards to TPTD’s effects on bone, it is known that
bone formation is promoted via TPTD’s effects on the
stimulation of osteoblast progenitor proliferation [17].
Another effect of TPTD on bone is the promotion of bone
resorption mediated through RANKL expression stimula-
tion [18]. The primary effects of TPTD from the perspec-
tive of calcium and phosphate metabolism are the
promotion of bone resorption and renal calcium reabsorp-
tion and the suppression of renal phosphate reabsorption.
Table 3 Multiple regression
analysis for change in L-BMD
at 72 weeks
Model Item Estimate SE p R2
1 Age -0.01 0.09 0.890 0.090
BMI 0.29 0.17 0.091
L-BMD at 0 weeks -0.10 0.05 0.041
Serum phosphate at 4 weeks 2.46 1.21 0.044
2 Age -0.03 0.09 0.783 0.094
BMI 0.29 0.17 0.089
L-BMD at 0 weeks -0.09 0.05 0.068





















































TmP/GFR at 4 weeks
P = 0.032
(a) (b)
Fig. 2 Differences in changes of L-BMD by serum phosphate and TmP/GFR category. a serum phosphate and L-BMD and b TmP/GFR and
L-BMD
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TPTD, therefore, could have dual effects, regulation of
calcium and phosphate metabolism via its physiological
actions on bone and kidney and bone formation via its
pharmacological actions on bone-forming cells. Therefore,
when primarily considering bone formation, because
appropriate levels of calcium and phosphate are necessary
for the mineralization of the bone matrix, the decrease in
serum phosphate concentration is postulated to be unfa-
vorable in bone mineralization, resulting in less BMD
acquisition. Indeed, osteomalacia caused by decreased
bone mineralization is sometimes observed in patients with
severe primary hyperparathyroidism or in patients with
secondary hyperparathyroidism undergoing dialysis [19].
Since renal tubule phosphate reabsorption decreased
with TPTD administration in the present study, a signif-
icant decrease in serum phosphate concentration was
observed. The degree of this decrease might affect the
extent of bone matrix mineralization reflecting BMD,
because there was a positive correlation between Tmp/
GFR and the percent increase in L-BMD with TPTD
treatment. This suggests that the greater the decrease of
phosphate reabsorption with TPTD treatment, the less
beneficial it is to BMD elevation. It is unlikely that the
direct effects of TPTD given once a week persist until
immediately prior to the subsequent treatment. Therefore,
it is postulated that the greater the re-elevation of
endogenous PTH after its transient suppression with
TPTD treatment, the lower the phosphate reabsorption
immediately before TPTD treatment and the less the
increase in BMD. Otherwise, once-weekly TPTD could
repeatedly stimulate the secretion of FGF23 that inhibits
renal phosphate reabsorption and vitamin D activation and
might decrease serum phosphate levels via the stimulation
of FGF23, when vitamin D stores are insufficient due to
vitamin D insufficiency/deficiency.
In general, the factor that is considered to most strongly
affect circulating PTH levels in individuals with normal
renal function without abnormal parathyroid function is
vitamin D status [20, 21]. This signifies that, since circu-
lating PTH increases in response to vitamin D deficiency or
insufficiency, sufficient vitamin D levels appear to be
necessary to maintain PTH at a physiologically stable state.
Our findings suggest two distinct biological functions of
TPTD and PTH, bone formation promotion and calcium-
phosphate metabolism regulation, and that both of them act
independently from one another. In addition, it is possible
from the perspective of BMD elevation that a sufficient
vitamin D level is necessary to suppress the promotion of
endogenous PTH secretion and to minimize the decrease in
serum phosphate concentration during TPTD treatment.
The present results suggest that further increases in BMD
may be attained by more vitamin D supplementation when
there is a marked decrease in serum phosphate
concentration during TPTD treatment. Alternatively, larger
and/or longer suppression of endogenous PTH by TPTD
might be involved in greater BMD acquisition along with
less decrease in serum phosphate irrespective of vitamin D
sufficiency.
There are several limitations to this study. First, this
study did not measure the endogenous concentration of
PTH. It is therefore not clear whether the present results are
a direct effect of TPTD or an indirect effect mediated via
endogenous PTH. Second, 25-hydroxy vitamin D concen-
tration before TPTD treatment was not measured, and the
state of vitamin D sufficiency was, therefore, unknown.
Moreover, while patients received native vitamin D sup-
plementation, the amount was relatively low at 400 IU/day,
and whether this amount adequately improved vitamin D
deficiency or insufficiency is not known.
In summary, this study suggests that the L-BMD
response to once-weekly long-term TPTD treatment is
associated with circulating phosphate and the status of its
renal reabsorption. To prevent the decrease in the serum
phosphate level, for example, with ample vitamin D sup-
plementation, may be important in acquiring greater BMD
with once-weekly TPTD.
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